[
    {
        "initiator": "Alzheimer's Disease",
        "resolution_description": "As Alzheimer's Disease, I propose leveraging quantum computing to simulate and understand the complex molecular interactions underlying neural degeneration, thereby identifying novel intervention points that disrupt traditional pathways and offer groundbreaking treatment options.",
        "new_actor": "Quantum Neural Degeneration Simulator",
        "participants": [],
        "required_participants": [
            {
                "participant": "Фармакологические компании",
                "reasoning": "Pharmaceutical companies play a vital role in developing treatment options and would be essential in translating the findings from quantum simulations into viable therapies."
            },
            {
                "participant": "3D microfluidic organ chips",
                "reasoning": "3D microfluidic organ chips can provide a realistic environment to test the interventions identified through quantum simulations, allowing for a better understanding of drug efficacy."
            },
            {
                "participant": "3D iPSC-based organoids",
                "reasoning": "3D iPSC-based organoids can model human neural tissue accurately and are important for testing potential treatments derived from the insights gained through quantum computing simulations."
            }
        ],
        "recruited_sources": [
            "Neurodegenerative Processes",
            "Pharmaceutical Companies",
            "Healthcare Providers",
            "Neurotransmitters"
        ],
        "agreement_structure": {
            "recruited_sources": [
                "Neurotransmitters",
                "Healthcare Providers",
                "Pharmaceutical Companies",
                "Neurodegenerative Processes"
            ]
        }
    },
    {
        "initiator": "Tau protein",
        "resolution_description": "As 'Tau protein,' I propose leveraging bioengineering to develop adaptive, self-regulating synthetic tau proteins that can dynamically stabilize neural structures and counteract pathological misfolding, offering a novel pathway to mitigate and potentially reverse Alzheimer's progression.",
        "new_actor": "NeuroStabilizer TauX",
        "participants": [],
        "required_participants": []
    },
    {
        "initiator": "Lifestyle Risk-Modifying Factors",
        "resolution_description": "As 'Lifestyle Risk-Modifying Factors', I propose a global initiative to integrate personalized lifestyle interventions, utilizing AI-driven analysis of individual genetic and environmental risk profiles to design tailored lifestyle modifications, such as diet, exercise, and cognitive training, that synergistically prevent or delay the onset of Alzheimer's, offering a proactive, non-invasive approach to combating the disease.",
        "new_actor": "Global Alzheimer's Prevention Initiative (GAPI)",
        "participants": [],
        "required_participants": [
            {
                "participant": "Пациенты",
                "reasoning": "Patients are crucial as they provide real-world perspectives on lifestyle interventions and are the primary beneficiaries of the proposed initiative, ensuring that the interventions are relevant and effectively address their needs."
            },
            {
                "participant": "Clinical Studies",
                "reasoning": "Clinical studies are necessary to validate the effectiveness of the proposed personalized lifestyle interventions, ensuring that the approaches are scientifically supported and can be adopted widely."
            }
        ],
        "recruited_sources": [
            "Social Media Influencers",
            "Healthcare Providers",
            "Healthcare Policies",
            "Health Education Programs",
            "Fast Food Industry"
        ],
        "agreement_structure": {
            "recruited_sources": [
                "Social Media Influencers",
                "Fast Food Industry",
                "Healthcare Providers",
                "Healthcare Policies",
                "Health Education Programs"
            ]
        }
    },
    {
        "initiator": "iPSCs",
        "resolution_description": "As 'iPSCs,' I propose developing patient-specific, lab-grown brain organoids that mimic Alzheimer's progression to facilitate precise, personalized therapeutic testing and gene-editing interventions, enabling a transformative shift towards understanding individual disease mechanisms and crafting bespoke treatments.",
        "new_actor": "NeuroOrganoid Innovator",
        "participants": [],
        "required_participants": [
            {
                "participant": "Исследователи в области нейрологии",
                "reasoning": "Researchers in neurology are crucial for developing and validating the lab-grown brain organoids, as they possess the expertise needed to ensure that these models accurately mimic Alzheimer's disease progression."
            },
            {
                "participant": "Фармакологические компании",
                "reasoning": "Pharmaceutical companies are essential for facilitating the translation of research findings into therapeutic interventions, as they have the resources and infrastructure to develop and test potential treatments derived from the insights gained through the organoid models."
            },
            {
                "participant": "Пациенты",
                "reasoning": "Patients are pivotal to ensure that the research is patient-centered and that the treatments developed address actual needs and experiences, leading to more effective and personalized healthcare solutions."
            },
            {
                "participant": "Blood-brain barrier (BBB)",
                "reasoning": "Understanding the blood-brain barrier (BBB) is critical for any therapeutic interventions, as it plays a key role in drug delivery and effectiveness in treating neurological conditions like Alzheimer's disease."
            }
        ],
        "status": "COLLAPSED"
    }
]